Tag: conatus pharmaceuticals

February 12, 2019

Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan

Conatus Pharmaceuticals (NASDAQ:CNAT) has announced it has finished enrollment of ENCORE-LF, a phase 2b clinical trial. As quoted in the...
January 13, 2019

5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week

Axsome Therapeutics, Checkpoint Therapeutics, Bellerophon Therapeutics, Enochian Bioscience and Equillium were last week's top gainers.
December 5, 2018

Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

Conatus Pharmaceuticals (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects...